title: Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma.
abstract: BACKGROUND
  Antihistamines have been shown to have a variety of therapeutic effects in asthma. Although nasal obstruction may play an important role in modulating lower airway function, no prior trial has used a decongestant in combination with an antihistamine in patients with allergic rhinitis and concomitant asthma.
  
  
  OBJECTIVE
  We sought to determine the efficacy and safety of loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P) twice daily in patients with seasonal allergic rhinitis and mild asthma.
  
  
  METHODS
  We conducted a randomized, double-blind, placebo-controlled trial of L/P in 193 subjects during the fall allergy season. Nasal and chest symptoms, albuterol use, and peak expiratory flow rates were recorded daily for 6 weeks. Spirometry was measured at baseline and after 1, 2, 4, and 6 weeks of therapy, and health-related quality of life was rated at the beginning and end of the study.
  
  
  RESULTS
  Total rhinitis and asthma symptom severity scores were significantly reduced in patients receiving active therapy compared with those receiving placebo throughout the 6-week study. Peak expiratory flow rates improved significantly in patients treated with L/P during weeks 2 through 6 (peak effect [mean +/- SEM]: L/P, 26.23 +/- 4.64 L/min vs placebo, 8.52 +/- 3.53 L/min, p = 0.002) as did FEV1 (peak effect [mean +/- SEM]: L/P, 170 +/- 53 ml vs placebo, 20 +/- 40 ml, p = 0.01) at all clinic visits. In addition, select measures of asthma-specific quality of life improved significantly relative to placebo.
  
  
  CONCLUSIONS
  L/P significantly improved nasal and asthma symptoms, pulmonary function, and quality of life in patients with seasonal allergic rhinitis and concomitant mild asthma.
authors.affiliation: Allergy Research Foundation, Inc., Los Angeles, CA 90025, USA.
authors.forename: J
authors.initials: J
authors.lastname: Corren
authors.forename: A G
authors.initials: AG
authors.lastname: Harris
authors.forename: D
authors.initials: D
authors.lastname: Aaronson
authors.forename: W
authors.initials: W
authors.lastname: Beaucher
authors.forename: R
authors.initials: R
authors.lastname: Berkowitz
authors.forename: E
authors.initials: E
authors.lastname: Bronsky
authors.forename: R
authors.initials: R
authors.lastname: Chen
authors.forename: P
authors.initials: P
authors.lastname: Chervinsky
authors.forename: R
authors.initials: R
authors.lastname: Cohen
authors.forename: J
authors.initials: J
authors.lastname: Fourre
authors.forename: J
authors.initials: J
authors.lastname: Grossman
authors.forename: E
authors.initials: E
authors.lastname: Meltzer
authors.forename: A
authors.initials: A
authors.lastname: Pedinoff
authors.forename: W
authors.initials: W
authors.lastname: Stricker
authors.forename: A
authors.initials: A
authors.lastname: Wanderer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004809:Ephedrine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017336:Loratadine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012129:Respiratory Function Tests; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D017336:Loratadine; D004809:Ephedrine; D000420:Albuterol